EMErna Magnusdottir

Erna Magnusdottir

*This is an algorithmically generated author record based on publicly available information.

Erna Magnusdottir has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the Feasibility of a Digital Therapeutic Program for Patients With Cancer During Active Treatment: Pre-Post Interventional Study

    by G Haukur Gudmundsson, Judit Mészáros, Ágústa E Björnsdóttir, María L Ámundadóttir, Gudrun E Thorvardardottir, Erna Magnusdottir, Halla Helgadottir, Saemundur Oddsson

    Background: Increasing evidence shows that lifestyle interventions can improve the symptoms, quality of life (QoL), and even overall survival of patients with cancer. Digital therapeutics (DTx) can help implement behavioral modifications and empower patients through education, lifestyle support, and remote symptom monitoring. Objective: We aimed to test the feasibility of a DTx program for patients with cancer, as measured by engagement, retention, and acceptability. In addition, we explored the effects of the program on cancer-related QoL. Methods: We conducted a 4-week single-arm trial in Iceland, where DTx was delivered through a smartphone app. The intervention consisted of patient education about mindfulness, sleep, stress, and nutrition; lifestyle coaching; and the completion of daily missions for tracking physical activity and exercise, reporting patient-reported outcomes (PROs), practicing mindfulness, and logging healthy food intake. Information on program engagement and retention, step goal attainment, as well as PROs were collected throughout the study. QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 at baseline and follow-up. Results: In total, 30 patients with cancer undergoing active therapy were enrolled, and 29 registered in the app (23 female, 18 with breast cancer; mean age 52.6, SD 11.5 years). Overall, 97% (28/29) of participants were active in 3 of the 4 weeks and completed the pre- and postprogram questionnaires. The weekly active days (median) were 6.8 (IQR 5.8-6.8), and 72% (21/29) of participants were active at least 5 days a week. Users interacted with the app on average 7.7 (SD 1.9) times per day. On week 1, all 29 participants used the step counter and logged an average of 20,306 steps; 21 (72%) participants reached their step goals of at least 3000 steps per day. On week 4, of the 28 active users, 27 (96%) were still logging their steps, with 19 (68%) reaching their step goals. Of the 28 participants who completed the satisfaction questionnaire, 25 (89%) were likely to recommend the program, 23 (82%) said the program helped them deal with the disease, and 24 (86%) said it helped them remember their medication. QoL assessment showed that the average global health status, functioning, and symptom burden remained stable from baseline to follow-up. In all, 50% (14/28) of participants reported less pain, and the average pain score decreased from 31 (SD 20.1) to 22.6 (SD 23.2; P=.16). There was no significant change in PROs on the quality of sleep, energy, and stress levels from the first to the last week. Conclusions: The high retention, engagement, and acceptability found in this study demonstrate that multidisciplinary DTx is feasible for patients with cancer. A longer, full-scale randomized controlled trial is currently being planned to evaluate the efficacy of the intervention.


  • Open Access

    Supporting Cancer Patients on Their Treatment Journey Towards Self-Efficacy: Usability Pilot Study of a Digital Therapeutic Solution (Preprint)

    by G. Haukur Gudmunsson, Judit Mészáros, Ágústa Björnsdóttir, María L. Ámundadóttir, Gudrun E. Thorvardardottir, Erna Magnusdottir, Halla Helgadottir, Saemundur Oddson

    BACKGROUND Digital lifestyle interventions can help cancer survivors better manage their disease through improved lifestyle choices. OBJECTIVE Our aim was to test the feasibility of a digital therapeutic (DTx) program for cancer patients, as measured by engagement, retention, and acceptability. We additionally explored the effects of the program on cancer-related quality of life. METHODS A four-week-long, single-arm trial was conducted in Iceland where the DTx was delivered through a smartphone app. The intervention consisted of completing daily missions (e.g., food logging, activity tracking, surveys) and receiving educational content about mindfulness, sleep, stress, and nutrition. Usage information such as engagement, retention, and step goal attainment, as well as patient-reported outcomes about energy, stress and quality of sleep were collected throughout the study. Cancer-specific quality of life using the EORTC QLQ-C30 questionnaire, as well as cardiovascular fitness and body composition were measured at baseline and follow-up. RESULTS Thirty cancer patients in active treatment were enrolled and 29 registered in the program (79% female, with mean age of 52.6 years, 62% with breast cancer). All 29 participants were active at least three out of four weeks, and 28 (97%) completed the pre- and post- program questionnaires. 72% were highly engaged, the median number of weekly active days were 6.8 (IQR: 5.8, 6.8), and mean daily mission interactions were 7.7 (SD = 1.9). On week one, all 29 participants used the step counter, and 72% reached their step goals; most of these individuals (n = 27) were still using the step counter on week four, with 70% reaching their step goals. The DTx had high acceptability, as 89% of participants said they were likely to recommend it, and 82% said the program helped them deal with the disease. Quality of life (QoL) assessment showed that global health status, functioning and symptom burden remained stable from baseline to follow-up. The largest improvement was observed in pain scores, which decreased from 31 (SD = 20.1) to 22.6 (SD = 23.2) (P= .16). CONCLUSIONS The high retention, engagement and acceptability found in this study demonstrate that a multidisciplinary DTx is feasible for cancer patients. A longer, full-scale randomized controlled trial (RCT) is currently being planned to evaluate the efficacy of the intervention.